Showing 7211-7220 of 9760 results for "".
- Valeant: FDA Issues Complete Response Letter for Duobriihttps://practicaldermatology.com/news/valeant-fda-issues-complete-response-letter-for-duobrii/2457723/Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. has received a Complete Response Letter (CRL) from the US FDA
- eRelevance Launches Suite of Services to Support Lead Conversionhttps://practicaldermatology.com/news/erelevance-launches-suite-of-services-to-support-lead-conversion/2457726/eRelevance Corporation has launched a suite of tech-powered services to help
- Galderma Global Survey Assesses Burden of Rosaceahttps://practicaldermatology.com/news/galderma-global-survey-assesses-burden-of-rosacea/2457732/Recently released findings from Galderma’s global survey on the true burden of rosacea suggest a need for dermatologists and doctors to proactively open a dialogue with patients about the true burden of rosacea. An expert-authored report entitled Rosacea:
- Luma Therapeutics Launches Novel illuvinate Phototherapy Systemhttps://practicaldermatology.com/news/luma-therapeutics-launches-novel-illuvinate-phototherapy-system/2457736/Luma Therapeutics has launched illuvinate as an innovative and modern twist on the Goeckerman regimen. By combining a narrowband UVB LED light with patented hydrogels containing coal tar micro-globules, illuvinate increases the skin's hydration, decreases inflammation, and suppresses overacti
- Avon Receives Patents for Rotational Infinite Effects Skincare Technologyhttps://practicaldermatology.com/news/avon-receives-patents-for-rotational-infinite-effects-skincare-technology/2457739/Avon has been issued two new patents for new technology currently included in the ANEW Reversalist Infinite Effects and most recently the ANEW Ultimate Infinite Effects products. The rotational regimen is designed to
- Spironolactone May Be an Alternative to Antibiotics in Female Acnehttps://practicaldermatology.com/news/spironolactone-may-be-an-alternative-to-antibiotics-in-female-acne/2457738/The diuretic drug spironolactone may be just as effective as antibiotics for the treatment of women’s acne, report researchers from the Perelman School of Medicine at the University of Pennsylvania. The study, published in the Journal of
- Eclipse Announces New Board Membershttps://practicaldermatology.com/news/eclipse-announces-new-board-members/2457740/Meet Eclipse’s Medical and Scientific Advisory Board (M&SAB) for 2018. The 2018 Eclipse M&SAB includes: Dr. Sanjay Batra Dr. Batra obtained his PhD in physiology from the University of Ottawa, C
- New PSA From American Academy of Dermatology Highlights Dangers of Tanninghttps://practicaldermatology.com/news/new-psa-from-american-academy-of-dermatology-highlights-dangers-of-tanning/2457753/As Memorial Day signals the unofficial start of summer, many teen girls will be eager to get out of school and spend time outside— and some may want to get a tan. But a new public service advertisement from the American Academy of Dermatology encourages those who are thinking of tanning to
- New Guidelines May Slightly Increase Reliability, Accuracy of Melanoma Diagnoseshttps://practicaldermatology.com/news/new-guidelines-may-slightly-increase-reliability-accuracy-of-melanoma-diagnoses/2457759/New guidelines may slightly increase reliability and accuracy of melanoma diagnoses, a new study in JAMA Network Open shows. The American Joint Committee on Cancer recently updated its guidelines for melanoma, and the study researchers found that when pathologists used the new gu
- Glenmark Pharmaceuticals Presents New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at IID Meetinghttps://practicaldermatology.com/news/glenmark-pharmaceuticals-presents-new-data-on-gbr-830-an-investigational-anti-ox40-monoclonal-antibody-at-iid-meeting/2457760/Glenmark Pharmaceuticals shared data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID)